Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
2010
Stress-induced transcription of satellite III repeats
2003
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
2008
Gene amplifications associated with the development of hormone-resistant prostate cancer.
2003
Tissue microarray technology in breast cancer HER2 diagnostics
2007
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
2006
The Molecular Analysis of Breast Cancer Utilizing Targeted Nanoparticle Based Ultrasound Contrast Agents
2005
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
2007
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
2003
External Quality Assurance of HER2 FISH and ISH Testing
2008
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 Standout
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
2007
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
2006
Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies
2010
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
2013
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis
2009
Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis
2015
Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients
2011
Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
2008
Very high quantitative tumor HER2 content and outcome in early breast cancer
2011
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
HER2Gene Amplification in Breast Cancer
2012
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
2007 Standout
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas
2008
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
2010
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
2007
Biologic and therapeutic role of HER2 in cancer
2003
The role of m6A RNA methylation in human cancer
2019 Standout
Quantitative PCR and HER2 Testing in Breast Cancer
2008
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer
2009
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
2008
Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations
2014
Chromogenic in situ hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization
2009
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
2009
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
2010
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
2011
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
2008 Standout
Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/ neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer
2008
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
2007
PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer
2007
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
2008
Determination ofHER2Amplification by In Situ Hybridization
2008
Adjusting for Partial Verification or Workup Bias in Meta-Analyses of Diagnostic Accuracy Studies
2012
Molecular determinants of resistance to antiandrogen therapy
2003 Standout
Determination of HER2 amplification in primary breast cancer using dual‐colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens
2010
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases
2005
A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH
2010
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
2007
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
2005
Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays
2009
Antibody therapy of cancer
2012 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Impact of Clinical and Non-Clinical Factors on the Choice of HER2 Test for Breast Cancer
2010
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
2013 StandoutNobel
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
2009 Standout
‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study
2016
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
2008
A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals
2007
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
2007
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions
2011
Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis
2003
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
2020 Standout
ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap
2015 Standout
The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network
2019
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Akt signalling in health and disease
2011 Standout
Anti‐cancer properties of anthraquinones from rhubarb
2006 Standout
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
2009
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
2005
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
HeterogeneousHER2Gene Amplification
2011
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Genomics: a preview of genomic medicine
2008
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
PI3K-Akt pathway: Its functions and alterations in human cancer
2004 Standout
Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics
2004
The Fibroblast Growth Factor signaling pathway
2015 Standout
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
2008
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
2004 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Monoclonal Antibodies for Cancer Therapy
2012 StandoutNobel
Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy
2007
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
2003
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
2006 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility
2014 StandoutNobel
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era
2006
Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus
2006
Androgen Receptor in Prostate Cancer
2004
Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results
2009
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Oncogenic protein tyrosine kinases
2004
Works of A.D. Watters being referenced
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
2003
Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer
2002
Gene amplification and overexpression of HER2 in renal cell carcinoma
2002
Interlaboratory Comparison ofHER-2Oncogene Amplification as Detected by Chromogenic and Fluorescencein situHybridization
2004
Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder
2000
Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder
2002
Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma
2003
Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
1998
HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
2003
Amplification of the androgen receptor may not explain the development of androgen‐independent prostate cancer
2001
Evaluating HER2 amplification and overexpression in breast cancer
2001
Progression to detrusor-muscle invasion in bladder carcinoma is associated with polysomy of chromosomes 1 and 8 in recurrent pTa/pT1 tumours
2002
Is Chromosome 9 Loss a Marker of Disease Recurrence in Transitional Cell Carcinoma of the Urinary Bladder?
1999